

LFM-A13, BTK inhibitor

Catalog	Unit
TBI1032-5MG	5 mg
TBI1032-25MG	25 mg

Product Details

Formal Name: (2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide

Molecular Formula: C₁₁H₈Br₂N₂O₂

Formula Weight: 360.00

CAS Number: 62004-35-7


Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 15 mg/ml) or in Ethanol (up to 15 mg/ml).

Storage: -20°C

Stability: ≥ 2 years.



Applications

BTK inhibitor

Functions

LFM-A13 is a selective inhibitor of Bruton's tyrosine kinase (BTK) – IC₅₀'s = 2.5 μM (recombinant BTK) and 17.2 μM (human BTK). It has also been shown to inhibit Polo-like kinase (PLK) – IC₅₀ = 61 μM for human PLK3. It displayed no activity (concentrations up to 278 μM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten tyrosine kinases.

Application Procedures

First dissolved in DMSO (up to 15 mg/ml) or in Ethanol (up to 15 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

For research use only.